Inventiva S.A. Sponsored ADR
Inventiva S.A. Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $9.0 million, down 43.7% from fiscal 2024.
Follow IVA
Inventiva S.A. Sponsored ADR (IVA) EV/Sales
As of 16 October 2026, Inventiva S.A. Sponsored ADR (IVA) trades at a EV/Sales of −0.1×. Over the past ten years it has ranged from −0.2× (October 2026) to 277× (June 2021); the current reading is higher than 0% of that period. That is below the Biotechnology industry median of 9.2× and below the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 5.4× | (17.39%) |
| FY2024 | 6.5× | (30.95%) |
| FY2023 | 9.5× | 37.85% |
| FY2022 | 6.9× | (88.39%) |
| FY2021 | 59.2× | 6.19% |
| FY2020 | 55.8× | 43.49% |
| FY2019 | 38.9× | 0.00% |
| FY2018 | 38.9× | 0.00% |
| FY2017 | 38.9× | 0.00% |
| FY2016 | 38.9× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2023 | 10.9× | 6.90% |
| Dec 2022 | 10.2× | (67.22%) |
| Jun 2022 | 31.2× | (60.11%) |
| Dec 2021 | 78.3× | (44.43%) |
| 8 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| IVA Inventiva S.A. Sponsored ADR | −0.1× |
| SANA Sana Biotechnology, Inc. compare | n/m |
| ANL Adlai Nortye Ltd. Sponsored ADR compare | n/m |
| IMMX Immix Biopharma, Inc. compare | n/m |
| DNA Ginkgo Bioworks Holdings, Inc. compare | 3.0× |
| GERN Geron Corporation compare | 3.3× |
| FDMT 4D Molecular Therapeutics, Inc. compare | 5.6× |
| LXRX Lexicon Pharmaceuticals, Inc. compare | 12.8× |
| ACHV Achieve Life Sciences, Inc. compare | 27.2× |
| Biotechnology industry median | 9.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)